- University of Virginia (B.A., 2001)
- William & Mary School of Law (J.D., 2004)
- District of Columbia and Virginia
- Hollingsworth LLP Hosts 30th Annual Defense Litigation Seminar amid the "noisiest" year ever.
- Hollingsworth LLP coaches student teams in GeoPlunge Tournament.
- Firm attorneys coach elementary school students in the 2015 Annual GeoPlunge Tournament.
- Firm Partners Named to the 2015 Washington, DC Edition of Super Lawyers
- New Jersey Superior Court grants Firm client Avon Products, Inc.’s motion for summary judgment in talc litigation.
Martinez v. American International Industries, et al., No. MID-L-1120-17AS (June 15, 2018)
- North Carolina federal jury returns complete defense verdict in favor of Novartis in Aredia®/Zometa® trial.
Earp v. Novartis Pharm. Corp., No. 5:11-cv-680-D (E.D.N.C. May 14, 2014)
- U.S. District Court for the Western District of Oklahoma grants summary judgment in favor of Novartis Pharmaceuticals Corporation.
Ingram v. Novartis Pharm. Corp., 888 F. Supp. 2d 1241 (W.D. Okla. 2012)
Kathryn S. Jensen specializes in the defense of complex serial and mass tort litigation, including the defense of personal injury litigation involving pharmaceutical products, medical devices, and alleged workplace exposures.
Ms. Jensen has defended corporate clients in serial mass tort litigation, statewide coordinated proceedings, individual state court proceedings, and federal multidistrict litigation in venues across the country. She has significant experience defending against all matter of legal claims involving FDA-regulated products, including product liability claims involving obstetrical drugs, contraceptives, gastrointestinal drugs, antiepileptics, oncology drugs, hernia products and contrast agents for magnetic resonance imaging. Ms. Jensen has also represented clients in toxic/environmental matters involving alleged exposures to asbestos and heavy metals, as well as purported injury claims stemming from a petroleum manufacturing plant fire.
Her broad range of litigation experience includes coordinating massive multi-national and electronic discovery efforts, preparing corporate witnesses for deposition and trial testimony, identifying and working with expert witnesses across many different fields, conducting and defending fact and expert witness depositions, engaging in motions practice, defending mediations, participating in trial teams, and appellate briefing. Notably, Ms. Jensen was part of the successful trial team to obtain a defense verdict in a pharmaceutical personal-injury case in federal court in Raleigh, North Carolina following a seven-day trial. Earp v. Novartis Pharm. Corp., No. 5:11-cv-680-D (E.D.N.C. May 14, 2014). In recognition of her familiarity with evolving corporate electronic document preservation and production obligations, Ms. Jensen has been named an "e-discovery liaison" in federal products liability litigation. She has also been instrumental in the successful resolution of many of the Firm’s complex cases prior to trial, including significant summary dispositions.
Ms. Jensen is named in the 2018 Washington, DC edition of Super Lawyers as a "Rising Star.” She is a member of the Defense Research Institute. In addition to her usual practice, she is also involved with the Firm’s pro bono activities, through her service as a guardian ad litem and coordinator of educational contests and volunteer programs with a local elementary school. She assists with the Firm’s recruiting efforts and serves as a super mentor to the Firm’s associates.
While at William and Mary School of Law, Ms. Jensen was a staff member of the Journal of Women and the Law, a student-edited journal focusing on gender-related issues and how gender bias in the law impacts women's lives and society as a whole. Before being elected to the partnership, Ms. Jensen was an Associate and a Summer Associate at the Firm.